Bill Dawson

Chairman

Professor Bill Dawson established a health care consultancy company, Bionet Ltd when he retired from Eli Lilly in 1996. Bionet advises companies and universities on exploitation of innovative research. At Lilly, Bill was in research management for almost 20 years, 14 as Director of Research in the UK and latterly as Director of Technology Acquisition, Europe. During his period at Lilly he took 17 compounds into development, two of which reached the market. He has published more than 100 papers, three of which were in Nature. He is a member of the academic liaison action group of ABPI. He was a Board member of the Pharmaceutical Licensing Group from 1993-2005.

He is a Director of Proteome Sciences plc, Novolytics Ltd, Pharmovation Ltd and Antitope Ltd as well as being a trustee of both the William Harvey Research Foundation and Northwick Park Institute of Medical Research.

Professor Dawson is a Governor of both the University of Brighton and De Montfort University and is an Advisory Board member of the Academy of Pharmaceutical Sciences, a member of the Royal Pharmaceutical Society Science Committee, the Royal Society of Chemistry Parliamentary Advisory Committee and the Biosciences Federation Education Committee.